Cancer Biology · global
Fructose May Weaken Adhesion Between Cancer Cells: Ovarian Cancer Study Reveals a New Mechanism of Spread
Cancer cells that survive chemotherapy may release fructose even after they stop dividing, making it easier for neighboring cells to detach from a tumor. This preclinical finding links cellular senescence, metabolism, and cancer spread, but is not yet sufficient to warrant changes to patients’ diets or medications.
When a cancer cell stops dividing, its effects on its surroundings do not necessarily stop. An ovarian cancer study found that some cells surviving chemotherapy release fructose, weakening neighboring cancer cells’ ability to adhere to one another and making it easier for them to detach from their original group. The study identifies a metabolic pathway worth investigating in how cancer continues to spread after treatment; the evidence currently comes from cell and animal experiments.
The study, published in *Nature Aging*, was conducted by first author Aidan Cole, senior author Katherine Aird, and colleagues at The Wistar Institute. The institute announced the findings in July this year, while a follow-up interview in August provided further details on the research direction. The recent coverage does not report new human trial results.
The team focused on chemotherapy-induced cellular senescence: these cancer cells no longer continue dividing but remain biologically active and can release molecules into their surroundings. The researchers collected their secretions and exposed other cancer cells to them, finding that the secretions alone could increase cancer cell dissemination in preclinical models. Further investigation of the components identified fructose as one of the key signals.
Fructose does more than provide energy. Through analyses including CRISPR screening, the team found that fructose inhibits cholesterol production in neighboring cancer cells, weakening adhesion between cells and making it easier for them to detach. This involves metabolic changes within cancer cells; blood cholesterol levels cannot be used directly as an indicator of cancer spread.
Diet also emerged in this line of research. Aird told Medical News Today that a high-fructose diet increased cancer spread in preclinical models even without chemotherapy. However, this does not establish how much fructose consumed in everyday life would affect the course of a patient’s disease, nor has it been confirmed that restricting fructose can reduce recurrence or metastasis. It also cannot be used to infer that eating fruit would produce the same results.
The role of cholesterol also led the researchers to examine statins, a class of cholesterol-lowering drugs. In experiments, the team observed that these drugs might likewise weaken cancer cell adhesion and promote detachment, but whether the same effects occur in patients has not been confirmed. The researchers explicitly emphasized that this is not a reason to stop taking prescribed statins, nor is it sufficient grounds for adjusting chemotherapy.
The next step is to determine whether this metabolic influence between cells can be blocked. In the interview, Aird revealed that the team is conducting further preclinical research to test whether a diabetes drug already approved in the United States can reduce fructose production by cells that survive chemotherapy. The drug’s name was not disclosed. Ami Vaidya, a gynecologic oncologist who was not involved in the study, cautioned that moving from the discovery of a mechanism to care decisions still requires validation in human studies.